Selected research
Industry Research
Diagnostic Nuclear Medicines Industry Research Report 2026
Market perspective
The global Diagnostic Nuclear Medicines market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Diagnostic Nuclear Medicines is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Diagnostic Nuclear Medicines is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Diagnostic Nuclear Medicines is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Diagnostic Nuclear Medicines include Bracco Imaging, Cardinal Health, Curium Pharma, GE Healthcare, Jubilant Pharma, Lantheus, SIEMENS, Dongcheng and Eli Lilly, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Diagnostic Nuclear Medicines market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Diagnostic Nuclear Medicines Market by Company
Bracco Imaging
Cardinal Health
Curium Pharma
GE Healthcare
Jubilant Pharma
Lantheus
SIEMENS
Dongcheng
Eli Lilly
Novartis
China Isotope & Radiation
Diagnostic Nuclear Medicines Segment by Type
Tc-99m
F-18
Other
Diagnostic Nuclear Medicines Segment by Application
Oncology
Cardiology
Other
Diagnostic Nuclear Medicines Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Diagnostic Nuclear Medicines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Diagnostic Nuclear Medicines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Diagnostic Nuclear Medicines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Diagnostic Nuclear Medicines manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Diagnostic Nuclear Medicines by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Diagnostic Nuclear Medicines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Tc-99m
- F-18
- Other
Applications
- Oncology
- Cardiology
- Other
Companies covered
- Bracco Imaging
- Cardinal Health
- Curium Pharma
- GE Healthcare
- Jubilant Pharma
- Lantheus
- SIEMENS
- Dongcheng
- Eli Lilly
- Novartis
- China Isotope & Radiation
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Diagnostic Nuclear Medicines Market Size (2021-2032)
- 2.2.2 Global Diagnostic Nuclear Medicines Sales (2021-2032)
- 2.2.3 Global Diagnostic Nuclear Medicines Market Average Price (2021-2032)
- 2.3 Diagnostic Nuclear Medicines by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Tc-99m
- 2.3.3 F-18
- 2.3.4 Other
- 2.4 Diagnostic Nuclear Medicines by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Oncology
- 2.4.3 Cardiology
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Diagnostic Nuclear Medicines Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Diagnostic Nuclear Medicines Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Diagnostic Nuclear Medicines Revenue of Manufacturers (2021-2026)
- 3.4 Global Diagnostic Nuclear Medicines Average Price by Manufacturers (2021-2026)
- 3.5 Global Diagnostic Nuclear Medicines Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Diagnostic Nuclear Medicines, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Diagnostic Nuclear Medicines, Product Type & Application
- 3.8 Global Manufacturers of Diagnostic Nuclear Medicines, Established Date
- 3.9 Global Diagnostic Nuclear Medicines Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Bracco Imaging
- 4.1.1 Bracco Imaging Company Information
- 4.1.2 Bracco Imaging Business Overview
- 4.1.3 Bracco Imaging Diagnostic Nuclear Medicines Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Bracco Imaging Diagnostic Nuclear Medicines Product Portfolio
- 4.1.5 Bracco Imaging Recent Developments
- 4.2 Cardinal Health
- 4.2.1 Cardinal Health Company Information
- 4.2.2 Cardinal Health Business Overview
- 4.2.3 Cardinal Health Diagnostic Nuclear Medicines Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Cardinal Health Diagnostic Nuclear Medicines Product Portfolio
- 4.2.5 Cardinal Health Recent Developments
- 4.3 Curium Pharma
- 4.3.1 Curium Pharma Company Information
- 4.3.2 Curium Pharma Business Overview
- 4.3.3 Curium Pharma Diagnostic Nuclear Medicines Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Curium Pharma Diagnostic Nuclear Medicines Product Portfolio
- 4.3.5 Curium Pharma Recent Developments
- 4.4 GE Healthcare
- 4.4.1 GE Healthcare Company Information
- 4.4.2 GE Healthcare Business Overview
- 4.4.3 GE Healthcare Diagnostic Nuclear Medicines Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 GE Healthcare Diagnostic Nuclear Medicines Product Portfolio
- 4.4.5 GE Healthcare Recent Developments
- 4.5 Jubilant Pharma
- 4.5.1 Jubilant Pharma Company Information
- 4.5.2 Jubilant Pharma Business Overview
- 4.5.3 Jubilant Pharma Diagnostic Nuclear Medicines Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Jubilant Pharma Diagnostic Nuclear Medicines Product Portfolio
- 4.5.5 Jubilant Pharma Recent Developments
- 4.6 Lantheus
- 4.6.1 Lantheus Company Information
- 4.6.2 Lantheus Business Overview
- 4.6.3 Lantheus Diagnostic Nuclear Medicines Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Lantheus Diagnostic Nuclear Medicines Product Portfolio
- 4.6.5 Lantheus Recent Developments
- 4.7 SIEMENS
- 4.7.1 SIEMENS Company Information
- 4.7.2 SIEMENS Business Overview
- 4.7.3 SIEMENS Diagnostic Nuclear Medicines Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 SIEMENS Diagnostic Nuclear Medicines Product Portfolio
- 4.7.5 SIEMENS Recent Developments
- 4.8 Dongcheng
- 4.8.1 Dongcheng Company Information
- 4.8.2 Dongcheng Business Overview
- 4.8.3 Dongcheng Diagnostic Nuclear Medicines Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Dongcheng Diagnostic Nuclear Medicines Product Portfolio
- 4.8.5 Dongcheng Recent Developments
- 4.9 Eli Lilly
- 4.9.1 Eli Lilly Company Information
- 4.9.2 Eli Lilly Business Overview
- 4.9.3 Eli Lilly Diagnostic Nuclear Medicines Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Eli Lilly Diagnostic Nuclear Medicines Product Portfolio
- 4.9.5 Eli Lilly Recent Developments
- 4.10 Novartis
- 4.10.1 Novartis Company Information
- 4.10.2 Novartis Business Overview
- 4.10.3 Novartis Diagnostic Nuclear Medicines Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Novartis Diagnostic Nuclear Medicines Product Portfolio
- 4.10.5 Novartis Recent Developments
- 4.11 China Isotope & Radiation
- 4.11.1 China Isotope & Radiation Company Information
- 4.11.2 China Isotope & Radiation Business Overview
- 4.11.3 China Isotope & Radiation Diagnostic Nuclear Medicines Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 China Isotope & Radiation Diagnostic Nuclear Medicines Product Portfolio
- 4.11.5 China Isotope & Radiation Recent Developments
5 Global Diagnostic Nuclear Medicines Market Scenario by Region
- 5.1 Global Diagnostic Nuclear Medicines Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Diagnostic Nuclear Medicines Sales by Region: 2021-2032
- 5.2.1 Global Diagnostic Nuclear Medicines Sales by Region: 2021-2026
- 5.2.2 Global Diagnostic Nuclear Medicines Sales by Region: 2027-2032
- 5.3 Global Diagnostic Nuclear Medicines Revenue by Region: 2021-2032
- 5.3.1 Global Diagnostic Nuclear Medicines Revenue by Region: 2021-2026
- 5.3.2 Global Diagnostic Nuclear Medicines Revenue by Region: 2027-2032
- 5.4 North America Diagnostic Nuclear Medicines Market Facts & Figures by Country
- 5.4.1 North America Diagnostic Nuclear Medicines Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Diagnostic Nuclear Medicines Sales by Country (2021-2032)
- 5.4.3 North America Diagnostic Nuclear Medicines Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Diagnostic Nuclear Medicines Market Facts & Figures by Country
- 5.5.1 Europe Diagnostic Nuclear Medicines Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Diagnostic Nuclear Medicines Sales by Country (2021-2032)
- 5.5.3 Europe Diagnostic Nuclear Medicines Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Diagnostic Nuclear Medicines Market Facts & Figures by Country
- 5.6.1 Asia Pacific Diagnostic Nuclear Medicines Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Diagnostic Nuclear Medicines Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Diagnostic Nuclear Medicines Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Diagnostic Nuclear Medicines Market Facts & Figures by Country
- 5.7.1 South America Diagnostic Nuclear Medicines Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Diagnostic Nuclear Medicines Sales by Country (2021-2032)
- 5.7.3 South America Diagnostic Nuclear Medicines Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Diagnostic Nuclear Medicines Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Diagnostic Nuclear Medicines Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Diagnostic Nuclear Medicines Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Diagnostic Nuclear Medicines Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Diagnostic Nuclear Medicines Sales by Type (2021-2032)
- 6.1.1 Global Diagnostic Nuclear Medicines Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Diagnostic Nuclear Medicines Sales Market Share by Type (2021-2032)
- 6.2 Global Diagnostic Nuclear Medicines Revenue by Type (2021-2032)
- 6.2.1 Global Diagnostic Nuclear Medicines Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Diagnostic Nuclear Medicines Revenue Market Share by Type (2021-2032)
- 6.3 Global Diagnostic Nuclear Medicines Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Diagnostic Nuclear Medicines Sales by Application (2021-2032)
- 7.1.1 Global Diagnostic Nuclear Medicines Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Diagnostic Nuclear Medicines Sales Market Share by Application (2021-2032)
- 7.2 Global Diagnostic Nuclear Medicines Revenue by Application (2021-2032)
- 7.2.1 Global Diagnostic Nuclear Medicines Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Diagnostic Nuclear Medicines Revenue Market Share by Application (2021-2032)
- 7.3 Global Diagnostic Nuclear Medicines Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Diagnostic Nuclear Medicines Value Chain Analysis
- 8.1.1 Diagnostic Nuclear Medicines Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Diagnostic Nuclear Medicines Production Mode & Process
- 8.2 Diagnostic Nuclear Medicines Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Diagnostic Nuclear Medicines Distributors
- 8.2.3 Diagnostic Nuclear Medicines Customers
9 Global Diagnostic Nuclear Medicines Analyzing Market Dynamics
- 9.1 Diagnostic Nuclear Medicines Industry Trends
- 9.2 Diagnostic Nuclear Medicines Industry Drivers
- 9.3 Diagnostic Nuclear Medicines Industry Opportunities and Challenges
- 9.4 Diagnostic Nuclear Medicines Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst